PBMC telomerase activity in depression and the response to electroconvulsive therapy.

Publication date: Jul 15, 2021

Telomerase, the DNA polymerase responsible for maintaining telomere length, has previously been implicated in depression and the response to antidepressant drugs. In this study, we aimed to compare telomerase activity in peripheral blood mononuclear cells between patients with severe depression recruited as part of the KEEP-WELL Trial (Ketamine for Depression Relapse Prevention Following ECT; NCT02414932) and age- and sex-matched healthy volunteers both at baseline/pre-ECT and at follow-up 1 month later for controls or in patients after a course of ECT. We found no differences in telomerase activity between patients with depression (n = 20) compared to healthy controls (n = 33) at baseline/pre-ECT, or between patients treated with ECT compared to controls at follow-up. In patients, telomerase activity was not associated with mood, as assessed by the 24-item Hamilton Rating Scale for Depression, or the duration of the current depressive episode. Additionally, we found no significant relationship between telomerase activity and exposure to recent or childhood adversity in either the patient or control groups. Overall, our results suggest that telomerase activity is not associated with depression, the therapeutic response to ECT, or exposure to adversity.

Open Access PDF

Concepts Keywords
Drugs Electroconvulsive therapy
Genes Telomerase
Nct02414932 Senescence
Therapy Ribonucleoproteins
DNA replication
Psychiatric diagnosis
Major depressive disorder
Branches of biology


Type Source Name
disease MESH depression
drug DRUGBANK Ketamine
disease MESH Relapse
disease MESH major depressive disorder
disease MESH aging
disease MESH Telomere shortening
pathway KEGG Cellular senescence
pathway KEGG Apoptosis
disease MESH anxiety
drug DRUGBANK Hydrocortisone
drug DRUGBANK Dextrose unspecified form
disease MESH Oxidative stress
disease MESH inflammation
disease MESH psychiatric illness
disease MESH psychological stress
drug DRUGBANK Serotonin
drug DRUGBANK Fluoxetine
drug DRUGBANK Sertraline
drug DRUGBANK Fenamole
disease MESH seizure
drug DRUGBANK Methohexital
drug DRUGBANK Choline
drug DRUGBANK Methionine
disease MESH dementia
disease MESH intellectual disability
disease MESH diagnosis
disease MESH alcohol dependence
drug DRUGBANK Trestolone
disease MESH violence
disease MESH separation
disease MESH Fasting
drug DRUGBANK Sodium Citrate
drug DRUGBANK Phosphate ion
drug DRUGBANK Nitrogen
drug DRUGBANK Water
disease MESH ulcerative colitis
disease MESH sarcoidosis
disease MESH neurological disorder
disease MESH adverse childhood experiences
drug DRUGBANK Coenzyme M
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Esketamine
disease MESH eating
disease MESH shock
drug DRUGBANK Sirolimus
drug DRUGBANK Desipramine
disease MESH lifestyle factors
drug DRUGBANK Copper
disease MESH depressive disorders
drug DRUGBANK Midazolam
drug DRUGBANK Nicotine
disease MESH diabetes mellitus
disease MESH cardiovascular risk factors
pathway KEGG Circadian rhythm

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *